Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients

BackgroundClinically, some patients whose HBsAg becomes negative owing to antiviral therapy or spontaneously still show a low level of HBV DNA persistence in serum. T-lymphocyte subsets, cytokine levels and HBV S gene sequences were analyzed in this study.MethodsA total of 52 HBsAg-negative and HBV...

Full description

Bibliographic Details
Published in:	Frontiers in Immunology
Main Authors:	Xin Liu, Shu-xiang Chen, Hui Liu, Jin-li Lou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Subjects:	T lymphocyte cytokine HBsAg negative HBV DNA Occult hepatitis B virus infection
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1211980/full

Similar Items

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
by: Lorenzo Piermatteo, et al.
Published: (2023-12-01)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
by: Romina Salpini, et al.
Published: (2020-01-01)

Investigation of HBV DNA in HBsAg positive patients
by: Nihal Secil Bati, et al.
Published: (2017-12-01)

Occult HBV Infection in Patients Infected by HIV or HCV: Comparison between HBV-DNA and Two Assays for HBsAg
by: Silvia Meschi, et al.
Published: (2024-03-01)

Analysis of S gene characteristic sequences and changes in properties of protein expression in HBV ASCs with low-level HBsAg
by: Yu Yu, et al.
Published: (2022-09-01)

HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure
by: Maryam Moini, et al.
Published: (2022-03-01)

Correlation between quantitative HBsAg and quantitative HBV DNA in chronic hepatitis B patients: a systematic review and meta-analysis
by: Ummi Maimunah, et al.
Published: (2024-05-01)

Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report
by: Maki Ohkubo, et al.
Published: (2023-12-01)

Identification and characteristics of mutations promoting occult HBV infection by ultrasensitive HBsAg assay
by: Shi Song, et al.
Published: (2025-05-01)

Effect of S-region mutations on HBsAg in HBsAg-negative HBV-infected patients
by: Hui Liu, et al.
Published: (2024-04-01)

Using the Quantitative Determination of HbsAg to Monitor Antiviral Therapy of Chronic HBV-Infection
by: I.A. Zaitsev
Published: (2015-04-01)

Rupestonic Acid Derivative YZH-106 Promotes Lysosomal Degradation of HBV L- and M-HBsAg via Direct Interaction with PreS2 Domain
by: Lanlan Liu, et al.
Published: (2024-07-01)

Baseline HBsAg quantitative and CD4 T cell counts are associated with HBsAg loss in people living with HIV/HBV coinfection after combined antiretroviral therapy
by: Muye Xia, et al.
Published: (2025-02-01)

Detection and prevalence of HBsAg and HBV DNA among visiting patients attending health facilities in Nigeria
by: Uchenna D. Abazuh, et al.
Published: (2023-07-01)

Detection of S-HBsAg Mutations in Patients with Hematologic Malignancies
by: Maria V. Konopleva, et al.
Published: (2021-05-01)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers
by: Luisa Roade, et al.
Published: (2023-10-01)

The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy
by: Yingfu Zeng, et al.
Published: (2024-03-01)

HBsAg and anti-HBs coexistence in patients with HBV in acute and chronic phases
by: Zhongshu Pu, et al.
Published: (2025-05-01)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
by: Ying Yan, et al.
Published: (2022-11-01)

Development of Low-Cost In-House Assays for Quantitative Detection of HBsAg, HBeAg, and HBV DNA to Enhance Hepatitis B Virus Diagnostics and Antiviral Screening in Resource-Limited Settings
by: Simmone D’souza, et al.
Published: (2025-03-01)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
by: Jaehyeon Lee, et al.
Published: (2023-02-01)

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
by: Hong Li, et al.
Published: (2022-12-01)

Geographic distribution of HBsAg subtypes in Brazil Distribuição geográfica dos subtipos de antígenos de HBsAg no Brasil
by: Ana Maria Coimbra Gaspar, et al.
Published: (1987-06-01)

HBV-RNA, Quantitative HBsAg, Levels of HBV in Peripheral Lymphocytes and HBV Mutation Profiles in Chronic Hepatitis B
by: Yael Gozlan, et al.
Published: (2022-03-01)

Potential infectivity of blood from HBsAG asymptomatic carriers due to the presence of HBV-DNA and comparison with other markers of hbv infection Potencial de infectividade em sangue de portadores assintomáticos de HBsAg caracterizado pela presença de HBV-DNA e comparação com outros marcadores da Hepatite B.
by: M. Valeria Tedeschi, et al.
Published: (1989-12-01)

A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivo
by: Min You, et al.
Published: (2023-12-01)

Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen
by: Joonhong Park, et al.
Published: (2021-11-01)

HIGH PREVALENCE OF HBsAg CARRIERS IN A SPECIFIC COMMUNITY IN BULGARIA
by: Zahariy Krastev, et al.
Published: (2011-10-01)

The relation of polymorphisms in +874 region of IFN-Gama with occult HBV infection
by: Kazemi Arababadi M (PhD), et al.
Published: (2010-03-01)

The PreS-Based Recombinant Vaccine VVX001 Induces Hepatitis B Virus Neutralizing Antibodies in a Low-Responder to HBsAg-Based HBV Vaccines
by: Inna Tulaeva, et al.
Published: (2024-09-01)

Performance Evaluation of a HBsAg-Specific Immunoadsorbent Based on a Humanized Anti-HBsAg Monoclonal Antibody
by: Shuangshuang Gao, et al.
Published: (2025-09-01)

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)
by: Mariantonietta Pisaturo, et al.
Published: (2019-09-01)

Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA
by: Jian Wang, et al.
Published: (2024-12-01)

HBsAg level defines different clinical phenotypes of HBeAg(−) chronic HBV infection related to HBV polymerase-specific CD8+ cell response quality
by: Julia Peña-Asensio, et al.
Published: (2024-03-01)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
by: Shaowen Jiang, et al.
Published: (2023-01-01)

Efficacy of extracorporeal immunoadsorption therapy for removal of HBsAg
by: Meng Wang, et al.
Published: (2025-07-01)

Occult HBV infection
by: I.A. Zaytsev
Published: (2018-04-01)

Seroprevalence of HIV-HBV Co-Infection
by: Suresh B. Sonth, et al.
Published: (2012-04-01)

HBeAg testing is better than quantitative HBsAg assay as an alternative to HBV DNA assay among HBV-infected pregnant women
by: Minh Ngoc Nguyen, et al.
Published: (2023-10-01)

Clinical implications of HBsAg quantification in patients with chronic hepatitis B
by: Mauro Viganò, et al.
Published: (2012-01-01)